XML 31 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Cash Equivalents, at Carrying Value $ 0   $ 0   $ 0
Payments to Acquire Available-for-sale Securities     2,847,736  
Proceeds from Sale of Available-for-sale Securities     1,695,000  
Available-for-sale Securities, Gross Realized Gain (Loss) 1,055 963  
Available-for-sale Securities, Gross Unrealized Gain (Loss)     (1,998)  
Available-for-sale Securities 1,151,701   1,151,701    
Goodwill, Impairment Loss $ 0 404,169 $ 404,169
Fair Value Assumptions, Expected Dividend Rate     0.00%    
Derivative, Gain (Loss) on Derivative, Net $ 68,965 $ (938) $ 81,509 $ (29,332)  
Private Placement [Member] | Series B Preferred Stock [Member] | Strategic Bio Partners [Member] | Debt Settlement [Member]          
Class of Warrant or Right, Issued     295,945    
Private Placement [Member] | Series B Preferred Stock [Member] | Placement Agent Warrants [Member]          
Class of Warrant or Right, Issued     127,346